Key facts
- It has raised $5.8M; the latest was Later Stage VC ($5.8M) in Sep 2025.
- Notable investors include European Innovation Council, European Union, Horizon 2020.
- Status: Privately Held (no backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ORF Genetics
- ·The full record, as it builds
Funding rounds
No funding rounds for ORF Genetics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ORF Genetics
Manufacturer and developer of high-quality recombinant proteins derived from barley plants based in Iceland. The company uses barley grain as a vehicle for recombinant protein production and produces taste-management protein and a group of ice-structuring proteins, to produce growth factors for cell-cultured meat which can revolutionize food tech, thereby enabling food, pharmaceutical, and cell-research industries to use biotechnology products for their production purpose.
- Sector
- Healthcare
- HQ
- Kopavogur, Iceland
- Founded
- 2001
- Employees
- 26
- Website
- orfgenetics.com/
- Ownership
- Privately Held (no backing)
ORF Genetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ORF Genetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ORF Genetics in its N-PORT filings yet. We sweep new filings monthly.